Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis.
Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis.
复制标题
DOI：
10.1007/s13555-021-00511-1
复制
发表时间：
2021-06
影响因子：
3.4
通讯作者：
Augustin M
中科院分区：
文献类型：
--
作者：
Armstrong AW;Soliman AM;Betts KA;Wang Y;Gao Y;Puig L;Augustin M
生物制剂和口服疗法治疗中重度斑块型银屑病的临床益处已得到充分证实，但不同疗法的疗效结果可能有所不同。比较疗效分析在具有多种治疗选择的临床环境中可以提供大量信息。这项研究评估了生物制剂和口服疗法治疗中重度银屑病的短期和长期疗效。系统性文献综述确定了截至 2020 年 7 月 1 日的 2/3/4 期随机对照试验 (RCT)，用于美国食品药品监督管理局或欧洲药品管理局许可的中度至重度银屑病治疗方法。使用贝叶斯网络荟萃分析估算主要缓解（短期：距基线 10-16 周）和维持期（长期：距基线 48-52 周）结束时的银屑病面积和严重程度指数 (PASI) 75/90/100 缓解率。累积排名曲线（SUCRA）下的表面被估计以呈现处理的相对排名。短期内（N = 71个RCT），ixekizumab（72.9%，SUCRA 0.951）、risankizumab（72.5%，0.940）和brodalumab（72.0%，0.930）的PASI 90缓解率最高，显着高于guselkumab（65.0%，0.930）。 0.795)、苏金单抗 (65.0%, 0.794)、英夫利昔单抗 (56.8%, 0.702)、赛妥珠单抗 (400 mg: 49.6%, 0.607;200 mg: 42.2%, 0.389)、乌特克单抗 (90 mg: 47.9%, 0.568;基于体重：45.7%，0.505；45 mg：44.6%，0.460）、阿达木单抗（43.0%，0.410）、tildrakizumab（200 mg：39.7%，0.327；100 mg：37.2%，0.268）、依那西普（18.0%， 0.171）、阿普斯特（12.4%，0.090）和富马酸二甲酯（12.2%，0.092）。 ixekizumab (41.4%)、risankizumab (40.8%) 和 brodalumab (40.3%) 的 PASI 100 缓解率最高。长期来看（N≥11个RCT），risankizumab的PASI 90率最高（85.3%，SUCRA：0.998），显着高于brodalumab（78.8%，0.786）、guselkumab（78.1%，0.760）、ixekizumab（72.1%， 0.577）、苏金单抗（67.0%，0.450）、乌特克单抗（基于体重：55.0%，0.252）、阿达木单抗（51.6%，0.176）和依那西普（37.9%，0.001）。 Risankizumab 的 PASI 100 缓解率最高 (65.4%)，其次是 brodalumab (55.7%) 和 guselkumab (54.8%)。 Ixekizumab、risankizumab 和 brodalumab 的短期疗效最高，risankizumab 的长期疗效最高。在线版本包含可在 10.1007/s13555-021-00511-1 获取的补充材料。
The clinical benefits of biologic and oral treatments for moderate-to-severe plaque psoriasis are well-established, but efficacy outcomes can vary across therapies. Comparative efficacy analysis can be highly informative in clinical settings with multiple therapeutic options. This study assessed the short-term and long-term comparative efficacy of biologic and oral treatments for moderate-to-severe psoriasis. A systematic literature review identified phase 2/3/4 randomized controlled trials (RCTs) through to 1 July 2020 for Food and Drug Administration- or European Medicines Agency-licensed treatments for moderate-to-severe psoriasis. Psoriasis Area and Severity Index (PASI) 75/90/100 response rates at the end of the primary response (short-term: 10–16 weeks from baseline) and maintenance periods (long-term: 48–52 weeks from baseline) were estimated using Bayesian network meta-analysis. Surfaces under the cumulative ranking curves (SUCRA) were estimated to present the relative ranking of treatments. In the short term (N = 71 RCTs), the PASI 90 response rates were highest for ixekizumab (72.9%, SUCRA 0.951), risankizumab (72.5%, 0.940), and brodalumab (72.0%, 0.930), which were significantly higher than those for guselkumab (65.0%, 0.795), secukinumab (65.0%, 0.794), infliximab (56.8%, 0.702), certolizumab (400 mg: 49.6%, 0.607; 200 mg: 42.2%, 0.389), ustekinumab (90 mg: 47.9%, 0.568; weight-based: 45.7%, 0.505; 45 mg: 44.6%, 0.460), adalimumab (43.0%, 0.410), tildrakizumab (200 mg: 39.7%, 0.327; 100 mg: 37.2%, 0.268), etanercept (18.0%, 0.171), apremilast (12.4%, 0.090), and dimethyl fumarate (12.2%, 0.092). The PASI 100 response rates were highest for ixekizumab (41.4%), risankizumab (40.8%), and brodalumab (40.3%). In the long term (N = 11 RCTs), the PASI 90 rate was highest for risankizumab (85.3%, SUCRA: 0.998), which were significantly higher than those for brodalumab (78.8%, 0.786), guselkumab (78.1%, 0.760), ixekizumab (72.1%, 0.577), secukinumab (67.0%, 0.450), ustekinumab (weight-based: 55.0%, 0.252), adalimumab (51.6%, 0.176), and etanercept (37.9%, 0.001). Risankizumab had the highest PASI 100 response rate (65.4%), followed by brodalumab (55.7%) and guselkumab (54.8%). Ixekizumab, risankizumab, and brodalumab had the highest short-term efficacy, and risankizumab had the highest long-term efficacy. The online version contains supplementary material available at 10.1007/s13555-021-00511-1.
登录
查看更多内容
影响因子：
168.9
作者：
Chaudhari, U;Romano, P;Gottlieb, AB
通讯作者：
Gottlieb, AB
影响因子：
168.9
作者：
Gordon, Kenneth B.;Strober, Bruce;Bachelez, Herve
通讯作者：
Bachelez, Herve
DOI：
10.1111/jdv.16558
发表时间：
2021-01
期刊：
Journal of the European Academy of Dermatology and Venereology : JEADV
影响因子：
--
作者：
Bagel J;Blauvelt A;Nia J;Hashim P;Patekar M;de Vera A;Ahmad K;Paguet B;Xia S;Muscianisi E;Lebwohl M
通讯作者：
Lebwohl M
影响因子：
2.3
作者：
Armstrong, April W.;Betts, Keith A.;Wu, Eric Q.
通讯作者：
Wu, Eric Q.
影响因子：
10.3
作者：
Blauvelt, A.;Prinz, J. C.;Cooper, S.
通讯作者：
Cooper, S.